Option chain shows key data for Inhibikase Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Inhibikase Therapeutics.

Inhibikase Therapeutics (NASDAQ:IKT) Stock, Option Chain

INHIBIKASE THERAPEUTICS INC

Inhibikase Therapeutics

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Analysts expect Ford Motor Co. (NYSE: F) to post quarterly earnings at 33 cents per share on revenue of $43.25 billion after the closing bell. Ford shares fell 0.7% to $10.09 in after-hours trading.

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

ACLS

ONON

STAA

This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

defence analysts

Initiation

Pre-Market Outlook

CDTX

CYTK

FLUT

IMNM

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Tesla's Gross Margin Shows Worst Is Behind, Creating A 'Goldilocks' Scenario For Bulls, Says Dan Ives — Elon Musk-Led EV Giant Surges Over 12% In After-Hours Trading

Movers

CARR

CCTG

CNSP

DBVT

GORO

ICLR

LRHC

MNDR

ORKT

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SDRL

SVRE

TSLA

VEEE

ZPTA

Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics Inc

iTokk Inc

INTERTEK GROUP PLC ORD by Intertek Group Plc

Intertek Group PLC

INTERTEK GROUP UNSP/ADR by Intertek Group Plc

Press Releases

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Earnings

Health Care

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

General

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Management

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Inhibikase Announces Expansion of Senior Leadership Team

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Cardiff Oncology

Editas Medicine

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibrx Biosciences

INmune Bio

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Nkarta

Puma Biotechnology

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tango Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Exagen

Jefferies

Comments

Inhibikase Therapeutics

Inhibikase Therapeutics (IKT) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell